Sun Pharmaceutical Industries Ltd Q1 FY27 Results — Earnings Call Analysis
Published 3 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹4.5L Cr
- Organon's current revenue growth is modest, around 1% to 2% annually. - Organon's current growth rate is flattish (1%-2%) for established products; growth acceleration depends on improved execution and in-licensing deals (Pages 21-22, 24).
From Sun Pharmaceutical Industries Ltd's Q1 FY27 earnings-call transcript · updated 3 Jul 2026.
Price
₹1,871
Market Cap
₹4.5L Cr
P/E Ratio
37.1
Revenue Rank
Margin Rank
How does Sun Pharmaceutical Industries Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sun Pharmaceutical Industries Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Sun Pharmaceutical Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹14.6K Cr, net profit ₹2.7K Cr.
Full financials →📊 Revenue & Sales Performance
Rank 4- →Organon's current revenue growth is modest, around 1% to 2% annually.
- →Sun Pharma aims to accelerate growth leveraging its robust execution capability and commercial footprint.
- →Growth strategies include scaling innovative products globally, entering 10 new markets using Sun's field force.
- →In-licensing of late-stage assets, especially in women's health and biosimilars, is a key driver for future growth.
- →Sales synergies from cross-selling Sun's portfolio through Organon's platform and vice versa are expected to boost revenue.
- →Focus on enhancing established brands by applying Sun's branded generic playbook to maintain or grow market share despite generic competition.
- →Investment in marketing and better execution aimed at improving growth without solely relying on in-licensing deals.
- →Long-term growth is prioritized, with no immediate detailed projections shared yet; more clarity expected post-integration and closing.
📈 Profitability & Margins
Rank 3- →Organon's current growth rate is flattish (1%-2%) for established products; growth acceleration depends on improved execution and in-licensing deals (Pages 21-22, 24).
- →Sun Pharma sees a long-term opportunity to transform and grow Organon's business, focusing on long-term value creation rather than short-term gains (Page 23).
- →EPS is expected to be accretive from the first full year post-transaction closing, with no major divestments required (Page 17).
- →Synergies estimated at $350 million mainly from cost savings in procurement, people, and supply chain (Page 12).
- →Growth drivers include leveraging Organon's commercial footprint, in-licensing innovative products (especially in women's health), and scaling biosimilars (Pages 11, 12, 13).
- →Management plans to invest as needed in in-licensing and commercialization to revive growth, especially for biosimilars and innovative products (Page 18).
🏗️ Capital Expenditure Plans
Yes💰 Fundraising & Capital Structure
Yes- →Sun Pharma will be taking on a significant amount of debt to close the Organon acquisition.
- →The combined company's net debt post-transaction is around 2.3 times EBITDA, considered manageable.
- →The company intends to focus on repaying this debt as early as possible using surplus cash flows.
- →They may refinance Organon's existing debt, which currently has an interest cost of about 5.5%, leveraging Sun Pharma's better credit rating for lower financing costs.
- →No specific plans for new equity fundraising were disclosed.
- →Dividend payments are expected to continue, though the final position will be shared after further clarity.
- →The company remains open to smaller, close-to-market acquisitions but no immediate funding plans for these were detailed.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Sun Pharmaceutical Industries Ltd Q1 FY27 results?
- Organon's current revenue growth is modest, around 1% to 2% annually. - Organon's current growth rate is flattish (1%-2%) for established products; growth acceleration depends on improved execution and in-licensing deals (Pages 21-22, 24).
What is Sun Pharmaceutical Industries Ltd share price analysis?
Sun Pharmaceutical Industries Ltd currently shows a neutral. The stock trades at a P/E of 37.1 with a market cap of ₹450,643. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharmaceutical Industries Ltd planning capital expenditure?
- The call transcript does not specifically mention detailed current or future capex figures.
Keep Sun Pharmaceutical Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.